Liposomes in dermatological diseases

Main Article Content

Manju Kamra A. Diwan


Liposomes are vesicles comprising of spherical phospholipids making them useful for topical applications of drugs. Liposome research has been expanded considerably and nowadays, it is possible to construct a wide range of liposomes varying in size, phospholipids composition and surface characteristics. In dermatological diseases, the topical application of liposomes has proven to be of high therapeutic value. Liposomes can be used as carriers for hydrophilic as well as lipophilic therapeutic agents because of their amphipathic character. They may improve stabilization of instable drugs by encapsulating them. They have the potential to target drugs into the pilosebaceous structures and hence have an advantage for treatment of hair follicle-associated disorders. Liposomal encapsulated drugs are found useful in the treatment of acne, atopic dermatitis, psoriasis, vitiligo, superficial vein thrombosis and hair removal etc

Article Details

How to Cite
KAMRA, Manju; DIWAN, A.. Liposomes in dermatological diseases. Journal of Applied Pharmaceutical Research, [S.l.], v. 5, n. 2, p. 1-8, apr. 2017. ISSN 2348-0335. Available at: <>. Date accessed: 25 june 2017.
Published Articles


[1] Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology, New York: Springer-Verlag, 2000.
[2] Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13: 238–252
[3] Schmid MH, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Del Rev. 1996; 18: 335–342.
[4] Hope MJ, Kitson CN. Liposomes: a perspective for dermatologists. Dermatol Clin. 1993; 11: 143–154.
[5] Egbaria K, Weiner N. Liposomes as a drug delivery system. Adv Drug Del Rev. 1990; 5: 287–300.
[6] Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008; 34: 203
[7] Grath JA, Uitto J. The filaggrin story. novel insights into skin barrier function and disease. Trends Mol Med .2008; 14: 20–27.
[8] Imokawa G, Akasaki S, Minematsu Y, Kawai M. Importance of intercellular lipids in water-retention properties of the stratum corneum: induction and recovery study of surfactant dry skin. Arch Dermatol Res .1989; 281: 45–51.
[9] Fartach M. Epidermal barrier in disorders of the skin. Micr Res Techn.1997; 38: 361–371.
[10] Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin. permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst.1996; 13: 257–388.
[11] Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transepidermal osmotic gradients and hydration force. BiochimBiophysActa. 1992; 1104: 226–232.
[12] Lieb L, Ramachandran C, Egbaria K, Weiner N. Topical delivery enhancement with multilamellar liposomes into pilosebaceous units. In vitro evaluation using fluorescent techniques with hamster ear model. J Invest Dermat.1992; 99: 108–113.
[13] Plessis J, Egbaria K, Weiner N. Influence of formulation factors on the deposition of liposomal components into the different strata of the skin. J SocCosmet Chem. 1992; 43: 93–100.
[14] Ostro M. Liposomes. Sci Am .1987; 256: 102–111.
[16] Banerjee R. Liposomes: Applications in Medicine. J Biomater Appl. 2001; 16: 3–21
[17] Barry BW. Penetration enhancers. In: ShrootB, SchäfferH, eds. Skin Pharmacokinetics. Karger, Basel, 1987: 121–127
[18] Dreher F, Walde P, Luist PL, Elsner P. Human skin irritation studies of a lecithin microemulsion gel and of lecithin liposomes. Skin Pharmacol. 1996; 9: 124–129.
[19] Patel H. Liposomes as a controlled-release system. BiochemSoc Trans .1985; 13: 513–516.
[20] Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin PharmacolPhysiol.2006; 19: 2–16.
[21] Brisaert M, Gabriëls M, Matthijs V, Plaizier–Vercammen J. Liposomes with tretinoin: a physical and chemical evaluation. J Pharm Biomed Anal. 2001; 26: 909–917.
[22] Mezei M, Gulasekharam V. Liposomes – a selective drug delivery system for the topical route of administration: lotion dosage form. Life Sci.1980; 26: 1473–1477.
[24] Honzak L, Sentjurc M. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Eur J Physiol.2000; 440 (Suppl.): 44–45.
[25] Schäfer-Korting M, Korting HC, Ponce-Pöschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Invest .1994; 72: 1086–1091.
[26] Patel VB, Misra AN, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol. 2000; 5: 455–464.
[27] Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoylperoxide for acne. Drug DevInd Pharm .2001; 27: 863–870.
[28] Fluhr JW, Barsom O, Gehring W, Gloor M. Antibacterial efficacy of benzoylperoxide in phopholipid liposomes. A vehicle-controlled, comparative study in patients with papulopustular acne. Dermatology. 1999; 198: 273–277.
[30] Irvine AD, McLean WHI. Breaking the (un) sound barrier: Filaggrin is a major gene for atopic dermatitis. J Invest Dermatol.2006; 126: 1200–1202.
[31] Palmer CNA, Irvine AD, Terron-Kwiatkowski A, Zhao Y. Common loss-of-function variants of the epidermal barrier protein filaggrin are major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38: 441–446.
[32] Lee JH, Lee SJ, Kim DS, Bang D. The effect of wet-wrap dressing on epidermal barrier in patients with atopic dermatitis. J EurAcadDermatolVenereol. 2007; 21: 1360–1368.
[33] Lautenschlager H. Liposomes in dermatological preparations. Cosmet Toiletries. 1990; 105: 89–96.
[34] Sveinsson SJ, Olafsson JH, Valgardsson VS. The effect of liposomal moisturizing cream on dry skin: a preliminary double-blind study. J Dermatol Treatment .1993; 4: 187–189.
[35] Korting HC, Zienicke H, Schafer-Korting M, Braun-Falco O. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J ClinPharmacol. 1990; 39: 349–351.
[37] Lebwohl M. Psoriasis. Lancet .2003; 361: 1197–1204.
[38] Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am AcadDermatol. 2005; 53: s94–s100.
[39] Körbel JN, Sebök B, Kerényl M, Mahrle G. Enhancement of the antiparakeratotic potency of calitriol and tacalcitol in liposomal preparations in the mouse tail test. Skin PharmacolAppl Skin Physiol. 2001; 14: 291–295.
[40] Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharmac. 2001; 228: 43–52.
[41] Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatol Treat. 2007; 18: 40–45.
[42] Verma DD, Fahr A. Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J Control Release. 2004; 97: 55–66.
[43] Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharmaceutics. 2004; 270: 119–125.
[44] Cui J, Shen L, Wang G. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol .1991; 97: 410–416.
[45] Ortel B, Tanew A, Honingsman H. treatment of vitiligo with khellin and ultraviolet A. J Am AcadDermatol. 1988; 18: 693–701.
[46] Orechia G, Sangalli ME, Gazzaniga A, Giordano F. Topical photochemotherapy of vitiligo with a new khellin formulation: preliminary results. J DermatolTreatm.1998; 9: 65–69.
[47] De Leeuw J, Van Der Beek N, Maierhofer G, Neugebauer WD. A case study to evaluate the treatment of vitiligo with khellin encapsulated in 1-phenylalanin stabilized phophatidylcholine liposomes in combination with ultraviolet light therapy. Eur J Dermat.2003; 13: 474–477.
[48] Kraemer K. Sunlight and skin cancer. ProcNatlAcadSci USA .1997; 94: 11–14.
[49] Dahl E, Aberg M, Rausing A, Rausing EL. Basal cell carcinoma. Cancer. 1992; 70: 104–108.
[50] De Vries E, Van De Poll-Franse LV, Louwman WJ, De Gruijl FR, Coebergh JWW. Predictions of skin cancer incidence in the Netherlands up to 2015. B J Dermatol. 2005; 152: 481–488.
[51] Ananthaswamy HN, Pierceall WE. Molecular mechanism of ultraviolet radiation carcinogenesis. PhotochemPhotobiol.1990; 52: 19–136.
[52] Tanaka K, Sekiguchi M, Okada Y. Restoration of ultraviolet-induced unscheduled DNA synthesis of xeroderma pigmentation cells by the concomitant treatment with bacteriophage T4 endonuclease V and HVJ (Sendai virus) ProcNatlAcadSci USA. 1975; 72: 4071–4075.
[53] Yarosh D. Liposome-encapsulated enzymes for DNA repair. In: Braun-FalcoO, KortingH, MaibachH, eds. Liposome Dermatics. Springer-Verlag, Berlin, 1992: 258–268. .
[54] Pierre MBR, Tedesco AC, Marchetti JM, Bentley MVLB. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: preparation and in vitro permeation study. BMC Dermatol. 2001; 1: 1–5.
[55] Panjehpour M, Julius CE, Phan MN, Vo-Dihn T, Overholt S. Laser-induced fluorescence spectroscopy for in vivo diagnosis of non-melanoma skin cancers. Lasers Surg Med..2002; 31: 367–373.
[57] Aghassi D, Anderson RR, Gonzalez S. Confocal laser microscopic imaging of actinic keratosis in vivo: a preliminary report. J Am AcadDermatol. 2000; 43: 42–48.
[58] Smits T, Kleinpenning MM, Blokx WAM, Van Der Kerkhof PCM, Van Erp PEJ, Gerritsen MJP. Fluorescence diagnosis in keratinocyticintraepidermalneoplasias. J Am AcadDermatol.2007; 57: 824–831.
[59] Kleinpenning MM, Smits T, Ewalds E, Van Erp PEJ, Van De Kerkhof PCM, Gerritsen MJP. Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. Br J Dermatol. 2006; 155: 539–545.
[60] Sand M, Bechara FG, Sand D, Altmeyer P, Hoffmann K. A randomized, controlled, double-blind study evaluating melanin-encapsulated liposomes as a chromophore for laser hair removal of blond, white, and grey hair. Ann Plast Surg. 2007; 58: 551–554.
[61] Tierney E, Goldberg DJ. Laser hair removal pearls. J Cosm Laser Ther.2008; 10: 17–23.
[62] Taddio A, KaurSoin H, Schuh S, Koren G, Scolni D. Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. CMAJ. 2005; 172: 1691–1695.
[63] Gold MH. Photodynamic therapy with lasers and intense pulsed light. Facial PlastSurgClin N Am .2007; 15: 145–160.
[64] Biter PH. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. DermatolSurg.2000; 26: 835–842.
[65] Touma D, Yaar M, Whitehead S. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol.2004; 140: 33–40.
[66] Olsen EA, Katz HI, Levine N. Tretinoin emollient cream: a new therapy for photodamaged skin. J Am AcadDermatol. 1992; 26: 215–224.
[67] Lippman SM, Meyskens FL. Results of the use of vitamin A and retinoids in cutaneous malignancies. PharmacTher.1989; 40: 107–122.
[68] Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda AM. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle–skin interaction. J Controlled Rel.2005; 103: 123–136.